Litcius/Paper detail

Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC

David Ross Camidge

2021Journal of Thoracic Oncology55 citationsDOI

Topics & Concepts

MedicineLine (geometry)OncologyInternal medicineFirst lineGeometryMathematicsLung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment